IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
IO Biotech, Inc. (IOBT)
Company Research
Source: GlobeNewswire
Completed enrollment of pivotal Phase 3 trial of lead investigational therapeutic cancer vaccine, IO102-IO103, in combination with KEYTRUDA® (pembrolizumab), in patients with advanced melanoma; planned interim analysis for overall response rate (ORR) expected in third quarter of 2024 by independent data monitoring committeeProgressed clinical development of IO102-IO103 with first patient dosed in Phase 2 basket trial of IO102-IO103 in combination with pembrolizumab as neoadjuvant and adjuvant treatment of patients with resectable solid tumorsEnded 2023 with cash and cash equivalents of approximately $143.2 million; expected operational runway into the fourth quarter of 2025 NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the fourth quarter and year-ended December 31, 2023. “In 2023, we
Show less
Read more
Impact Snapshot
Event Time:
IOBT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOBT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOBT alerts
High impacting IO Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
IOBT
News
- IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness [Yahoo! Finance]Yahoo! Finance
- IO Biotech Expands Senior Leadership Team to Progress Commercialization ReadinessGlobeNewswire
- IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103GlobeNewswire
- IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
IOBT
Earnings
- 11/13/23 - Beat
IOBT
Analyst Actions
- 3/6/24 - HC Wainwright
IOBT
Sec Filings
- 4/26/24 - Form 8-K
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- IOBT's page on the SEC website